COVID-19 Impact on Global Targeted Drug ALK Inhibitors for NSCLC Market Size, Status and Forecast 2020-2026

July 2020 | 99 pages | ID: C3574E73B0F6EN
QYResearch

Abstracts

This report focuses on the global Targeted Drug ALK Inhibitors for NSCLC status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Targeted Drug ALK Inhibitors for NSCLC development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Pfizer
• Novartis
• Chugai Pharmaceutical (Hoffmann-La Roche group)
• ARIAD Pharmaceuticals (Takeda)
• Genvio Pharma Limited
• Beacon Pharma Limited
• Drug International Limted
• Incepta Pharmaceuticals

Market segment by Type, the product can be split into

• Crizotinib
• Ceritinib
• Alectinib
• Brigatinib
• Lorlatinib
• Other

Market segment by Application, split into

• Squamous Cell Carcinoma of NSCLC
• Adenocarcinoma of NSCLC
• Large Cell Carcinoma of NSCLC

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Targeted Drug ALK Inhibitors for NSCLC status, future forecast, growth opportunity, key market and key players.
• To present the Targeted Drug ALK Inhibitors for NSCLC development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Targeted Drug ALK Inhibitors for NSCLC are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Targeted Drug ALK Inhibitors for NSCLC Revenue
1.4 Market Analysis by Type
  1.4.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Crizotinib
  1.4.3 Ceritinib
  1.4.4 Alectinib
  1.4.5 Brigatinib
  1.4.6 Lorlatinib
  1.4.7 Other
1.5 Market by Application
  1.5.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Application: 2020 VS 2026
  1.5.2 Squamous Cell Carcinoma of NSCLC
  1.5.3 Adenocarcinoma of NSCLC
  1.5.4 Large Cell Carcinoma of NSCLC
1.6 Coronavirus Disease 2019 (Covid-19): Targeted Drug ALK Inhibitors for NSCLC Industry Impact
  1.6.1 How the Covid-19 is Affecting the Targeted Drug ALK Inhibitors for NSCLC Industry
    1.6.1.1 Targeted Drug ALK Inhibitors for NSCLC Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Targeted Drug ALK Inhibitors for NSCLC Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Targeted Drug ALK Inhibitors for NSCLC Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Targeted Drug ALK Inhibitors for NSCLC Market Perspective (2015-2026)
2.2 Targeted Drug ALK Inhibitors for NSCLC Growth Trends by Regions
  2.2.1 Targeted Drug ALK Inhibitors for NSCLC Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Targeted Drug ALK Inhibitors for NSCLC Historic Market Share by Regions (2015-2020)
  2.2.3 Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Targeted Drug ALK Inhibitors for NSCLC Market Growth Strategy
  2.3.6 Primary Interviews with Key Targeted Drug ALK Inhibitors for NSCLC Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Market Size
  3.1.1 Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Revenue (2015-2020)
  3.1.2 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Players (2015-2020)
  3.1.3 Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Concentration Ratio
  3.2.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Targeted Drug ALK Inhibitors for NSCLC Revenue in 2019
3.3 Targeted Drug ALK Inhibitors for NSCLC Key Players Head office and Area Served
3.4 Key Players Targeted Drug ALK Inhibitors for NSCLC Product Solution and Service
3.5 Date of Enter into Targeted Drug ALK Inhibitors for NSCLC Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Targeted Drug ALK Inhibitors for NSCLC Historic Market Size by Type (2015-2020)
4.2 Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Type (2021-2026)

5 TARGETED DRUG ALK INHIBITORS FOR NSCLC BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2015-2020)
5.2 Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Targeted Drug ALK Inhibitors for NSCLC Market Size (2015-2020)
6.2 Targeted Drug ALK Inhibitors for NSCLC Key Players in North America (2019-2020)
6.3 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2015-2020)
6.4 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size (2015-2020)
7.2 Targeted Drug ALK Inhibitors for NSCLC Key Players in Europe (2019-2020)
7.3 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2015-2020)
7.4 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2015-2020)

8 CHINA

8.1 China Targeted Drug ALK Inhibitors for NSCLC Market Size (2015-2020)
8.2 Targeted Drug ALK Inhibitors for NSCLC Key Players in China (2019-2020)
8.3 China Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2015-2020)
8.4 China Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Targeted Drug ALK Inhibitors for NSCLC Market Size (2015-2020)
9.2 Targeted Drug ALK Inhibitors for NSCLC Key Players in Japan (2019-2020)
9.3 Japan Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2015-2020)
9.4 Japan Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size (2015-2020)
10.2 Targeted Drug ALK Inhibitors for NSCLC Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2015-2020)
10.4 Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2015-2020)

11 INDIA

11.1 India Targeted Drug ALK Inhibitors for NSCLC Market Size (2015-2020)
11.2 Targeted Drug ALK Inhibitors for NSCLC Key Players in India (2019-2020)
11.3 India Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2015-2020)
11.4 India Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Targeted Drug ALK Inhibitors for NSCLC Market Size (2015-2020)
12.2 Targeted Drug ALK Inhibitors for NSCLC Key Players in Central & South America (2019-2020)
12.3 Central & South America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2015-2020)
12.4 Central & South America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Pfizer
  13.1.1 Pfizer Company Details
  13.1.2 Pfizer Business Overview and Its Total Revenue
  13.1.3 Pfizer Targeted Drug ALK Inhibitors for NSCLC Introduction
  13.1.4 Pfizer Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020))
  13.1.5 Pfizer Recent Development
13.2 Novartis
  13.2.1 Novartis Company Details
  13.2.2 Novartis Business Overview and Its Total Revenue
  13.2.3 Novartis Targeted Drug ALK Inhibitors for NSCLC Introduction
  13.2.4 Novartis Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020)
  13.2.5 Novartis Recent Development
13.3 Chugai Pharmaceutical (Hoffmann-La Roche group)
  13.3.1 Chugai Pharmaceutical (Hoffmann-La Roche group) Company Details
  13.3.2 Chugai Pharmaceutical (Hoffmann-La Roche group) Business Overview and Its Total Revenue
  13.3.3 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Introduction
  13.3.4 Chugai Pharmaceutical (Hoffmann-La Roche group) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020)
  13.3.5 Chugai Pharmaceutical (Hoffmann-La Roche group) Recent Development
13.4 ARIAD Pharmaceuticals (Takeda)
  13.4.1 ARIAD Pharmaceuticals (Takeda) Company Details
  13.4.2 ARIAD Pharmaceuticals (Takeda) Business Overview and Its Total Revenue
  13.4.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Introduction
  13.4.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020)
  13.4.5 ARIAD Pharmaceuticals (Takeda) Recent Development
13.5 Genvio Pharma Limited
  13.5.1 Genvio Pharma Limited Company Details
  13.5.2 Genvio Pharma Limited Business Overview and Its Total Revenue
  13.5.3 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Introduction
  13.5.4 Genvio Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020)
  13.5.5 Genvio Pharma Limited Recent Development
13.6 Beacon Pharma Limited
  13.6.1 Beacon Pharma Limited Company Details
  13.6.2 Beacon Pharma Limited Business Overview and Its Total Revenue
  13.6.3 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Introduction
  13.6.4 Beacon Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020)
  13.6.5 Beacon Pharma Limited Recent Development
13.7 Drug International Limted
  13.7.1 Drug International Limted Company Details
  13.7.2 Drug International Limted Business Overview and Its Total Revenue
  13.7.3 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Introduction
  13.7.4 Drug International Limted Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020)
  13.7.5 Drug International Limted Recent Development
13.8 Incepta Pharmaceuticals
  13.8.1 Incepta Pharmaceuticals Company Details
  13.8.2 Incepta Pharmaceuticals Business Overview and Its Total Revenue
  13.8.3 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Introduction
  13.8.4 Incepta Pharmaceuticals Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020)
  13.8.5 Incepta Pharmaceuticals Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Targeted Drug ALK Inhibitors for NSCLC Key Market Segments
Table 2. Key Players Covered: Ranking by Targeted Drug ALK Inhibitors for NSCLC Revenue
Table 3. Ranking of Global Top Targeted Drug ALK Inhibitors for NSCLC Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Crizotinib
Table 6. Key Players of Ceritinib
Table 7. Key Players of Alectinib
Table 8. Key Players of Brigatinib
Table 9. Key Players of Lorlatinib
Table 10. Key Players of Other
Table 11. COVID-19 Impact Global Market: (Four Targeted Drug ALK Inhibitors for NSCLC Market Size Forecast Scenarios)
Table 12. Opportunities and Trends for Targeted Drug ALK Inhibitors for NSCLC Players in the COVID-19 Landscape
Table 13. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 14. Key Regions/Countries Measures against Covid-19 Impact
Table 15. Proposal for Targeted Drug ALK Inhibitors for NSCLC Players to Combat Covid-19 Impact
Table 16. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 17. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Regions (US$ Million): 2020 VS 2026
Table 18. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Regions (2015-2020) (US$ Million)
Table 19. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Regions (2015-2020)
Table 20. Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 21. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Regions (2021-2026)
Table 22. Market Top Trends
Table 23. Key Drivers: Impact Analysis
Table 24. Key Challenges
Table 25. Targeted Drug ALK Inhibitors for NSCLC Market Growth Strategy
Table 26. Main Points Interviewed from Key Targeted Drug ALK Inhibitors for NSCLC Players
Table 27. Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Players (2015-2020) (Million US$)
Table 28. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Players (2015-2020)
Table 29. Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drug ALK Inhibitors for NSCLC as of 2019)
Table 30. Global Targeted Drug ALK Inhibitors for NSCLC by Players Market Concentration Ratio (CR5 and HHI)
Table 31. Key Players Headquarters and Area Served
Table 32. Key Players Targeted Drug ALK Inhibitors for NSCLC Product Solution and Service
Table 33. Date of Enter into Targeted Drug ALK Inhibitors for NSCLC Market
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 36. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Share by Type (2015-2020)
Table 37. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Type (2021-2026)
Table 38. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Share by Application (2015-2020)
Table 39. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 40. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Share by Application (2021-2026)
Table 41. North America Key Players Targeted Drug ALK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 42. North America Key Players Targeted Drug ALK Inhibitors for NSCLC Market Share (2019-2020)
Table 43. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 44. North America Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 45. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 46. North America Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 47. Europe Key Players Targeted Drug ALK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 48. Europe Key Players Targeted Drug ALK Inhibitors for NSCLC Market Share (2019-2020)
Table 49. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 50. Europe Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 51. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 52. Europe Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 53. China Key Players Targeted Drug ALK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 54. China Key Players Targeted Drug ALK Inhibitors for NSCLC Market Share (2019-2020)
Table 55. China Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 56. China Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 57. China Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 58. China Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 59. Japan Key Players Targeted Drug ALK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 60. Japan Key Players Targeted Drug ALK Inhibitors for NSCLC Market Share (2019-2020)
Table 61. Japan Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 62. Japan Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 63. Japan Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 64. Japan Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 65. Southeast Asia Key Players Targeted Drug ALK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 66. Southeast Asia Key Players Targeted Drug ALK Inhibitors for NSCLC Market Share (2019-2020)
Table 67. Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 68. Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 69. Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 70. Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 71. India Key Players Targeted Drug ALK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 72. India Key Players Targeted Drug ALK Inhibitors for NSCLC Market Share (2019-2020)
Table 73. India Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 74. India Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 75. India Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 76. India Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 77. Central & South America Key Players Targeted Drug ALK Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 78. Central & South America Key Players Targeted Drug ALK Inhibitors for NSCLC Market Share (2019-2020)
Table 79. Central & South America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 80. Central & South America Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 81. Central & South America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 82. Central & South America Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 83. Pfizer Company Details
Table 84. Pfizer Business Overview
Table 85. Pfizer Product
Table 86. Pfizer Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 87. Pfizer Recent Development
Table 88. Novartis Company Details
Table 89. Novartis Business Overview
Table 90. Novartis Product
Table 91. Novartis Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 92. Novartis Recent Development
Table 93. Chugai Pharmaceutical (Hoffmann-La Roche group) Company Details
Table 94. Chugai Pharmaceutical (Hoffmann-La Roche group) Business Overview
Table 95. Chugai Pharmaceutical (Hoffmann-La Roche group) Product
Table 96. Chugai Pharmaceutical (Hoffmann-La Roche group) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 97. Chugai Pharmaceutical (Hoffmann-La Roche group) Recent Development
Table 98. ARIAD Pharmaceuticals (Takeda) Company Details
Table 99. ARIAD Pharmaceuticals (Takeda) Business Overview
Table 100. ARIAD Pharmaceuticals (Takeda) Product
Table 101. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 102. ARIAD Pharmaceuticals (Takeda) Recent Development
Table 103. Genvio Pharma Limited Company Details
Table 104. Genvio Pharma Limited Business Overview
Table 105. Genvio Pharma Limited Product
Table 106. Genvio Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 107. Genvio Pharma Limited Recent Development
Table 108. Beacon Pharma Limited Company Details
Table 109. Beacon Pharma Limited Business Overview
Table 110. Beacon Pharma Limited Product
Table 111. Beacon Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 112. Beacon Pharma Limited Recent Development
Table 113. Drug International Limted Company Details
Table 114. Drug International Limted Business Overview
Table 115. Drug International Limted Product
Table 116. Drug International Limted Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 117. Drug International Limted Recent Development
Table 118. Incepta Pharmaceuticals Business Overview
Table 119. Incepta Pharmaceuticals Product
Table 120. Incepta Pharmaceuticals Company Details
Table 121. Incepta Pharmaceuticals Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 122. Incepta Pharmaceuticals Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Type: 2020 VS 2026
Figure 2. Crizotinib Features
Figure 3. Ceritinib Features
Figure 4. Alectinib Features
Figure 5. Brigatinib Features
Figure 6. Lorlatinib Features
Figure 7. Other Features
Figure 8. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Application: 2020 VS 2026
Figure 9. Squamous Cell Carcinoma of NSCLC Case Studies
Figure 10. Adenocarcinoma of NSCLC Case Studies
Figure 11. Large Cell Carcinoma of NSCLC Case Studies
Figure 12. Targeted Drug ALK Inhibitors for NSCLC Report Years Considered
Figure 13. Global Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Regions: 2020 VS 2026
Figure 15. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Players in 2019
Figure 18. Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drug ALK Inhibitors for NSCLC as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Targeted Drug ALK Inhibitors for NSCLC Revenue in 2019
Figure 20. North America Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Pfizer Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020)
Figure 29. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Novartis Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020)
Figure 31. Chugai Pharmaceutical (Hoffmann-La Roche group) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Chugai Pharmaceutical (Hoffmann-La Roche group) Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020)
Figure 33. ARIAD Pharmaceuticals (Takeda) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020)
Figure 35. Genvio Pharma Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Genvio Pharma Limited Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020)
Figure 37. Beacon Pharma Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Beacon Pharma Limited Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020)
Figure 39. Drug International Limted Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Drug International Limted Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020)
Figure 41. Incepta Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Incepta Pharmaceuticals Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2015-2020)
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed